The benefits of antiretroviral therapy (ART) to HIV-infected patients are significant. However, ART interruption is coupled with a rapid rebound in plasma viremia. This rebound signifies the ultimate challenge surrounding ART - its inability to completely eradicate HIV. Understanding the mechanisms by which the virus is able to persist in the face of ART is necessary in order to identify strategies that may interrupt viral persistence and ultimately lead to virus eradication. There is a definite need for the implementation of in vivo models where these mechanisms can be elucidated and induction/eradication interventions aimed at virus eradication can be evaluated. Novel humanized mice (bone marrow-liver-thymus or BLT mice) developed in our laboratory could serve effectively in this capacity. Humanized BLT mice exhibit systemic reconstitution (including in the gut and vaginal mucosa) with a complete and functional human immune system. The functionality and usefulness of BLT mice in the study of HIV persistence and eradication will become evident when the following aims are completed, wherein the parameters of viral persistence will be established and novel eradication approaches will be tested. The long-term goal of our project is to develop and implement an in vivo animal model in which novel protocols for HIV-1 eradication can be evaluated. This project will first compare different drug regimens aimed at establishing durable suppression of viremia in humanized BLT mice to allow the detailed study of persistence and latency. We will then establish the sites of residual virus infection that persist despite ART. After the establishment of this model, this project will evaluate the effect of novel reagents to disrupt latency with the ultimate long-term goal of establishing virus eradication. Our goals will be achieved by pursuing the following specific aims:
Specific Aim 1 : To establish an optimal drug regimen for the durable suppression of viremia in humanized BLT mice.
Specific Aim 2 : To characterize the nature and the anatomical location of viral reservoirs which persist in BLT mice undergoing ART.
Specific Aim 3 : To characterize the effect of select induction therapeutic interventions for their ability to eradicate virus from infected BLT mice, by significantly delaying or preventing rebound after discontinuation of antiretroviral therapy. HIV eradication is a daunting task that has proven to be extremely difficult to achieve in patients. The significance of this project rests on its goal: to develop and implement a novel in vivo model in which eradication approaches aimed at the development of a potential
The research proposed in this application is innovative, in our opinion, because it represents a new and substantially different way of addressing a most important step in the discovery process towards a cure for HIV/AIDS: the development of validated in vivo systems for the evaluation of HIV eradication strategies. In essence, our approach of developing the humanized BLT model to study HIV latency and eradication represents an important departure from the status quo in the field with the significant potential of enabling new opportunities for the translation of laboratory observations into clinical implementation.
|Honeycutt, Jenna B; Sheridan, Patricia A; Matsushima, Glenn K et al. (2015) Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol 21:301-9|
|Manson McManamy, Mary E; Hakre, Shweta; Verdin, Eric M et al. (2014) Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother 23:145-9|
|King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5|
|Spivak, Adam M; Andrade, Adriana; Eisele, Evelyn et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58:883-90|
|Duverger, Alexandra; Wolschendorf, Frank; Anderson, Joshua C et al. (2014) Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 88:364-76|
|Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872|
|Abreu, Celina M; Price, Sarah L; Shirk, Erin N et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257|
|Archin, Nancie M; Margolis, David M (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35|
|Liu, Pingyang; Xiang, Yanhui; Fujinaga, Koh et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25|
|Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46|
Showing the most recent 10 out of 77 publications